871. Oral Ibrexafungerp Outcomes by Fungal Disease in Patients from an Interim Analysis of a Phase 3 Open-label Study (FURI)

BACKGROUND: There are limited oral treatment options for patients with fungal infections who fail currently available antifungals or have an infection caused by resistant organisms. Ibrexafungerp is an investigational broad-spectrum glucan synthase inhibitor with activity against Candida and Aspergi...

Descripción completa

Detalles Bibliográficos
Autores principales: Thompson, George R, King, Thomas, Azie, Nkechi, Angulo, David A, Prattes, Juergen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752190/
http://dx.doi.org/10.1093/ofid/ofac492.064

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752190/
http://dx.doi.org/10.1093/ofid/ofac492.064

Ejemplares similares